NXI Therapeutics AG

NXI Therapeutics is a spin-off from the Biozentrum, University of Basel, Switzerland founded by Prof. Jean Pieters and CSO Dr. med. Rajesh Jayachandran. The company focuses on clinical applications in T cell-mediated autoimmune conditions and is committed to creating tomorrow’s disruptive immunotherapies through modulation of coronin 1 in immune cells. The uniqueness of the thereby induced immunomodulation is its selectivity for auto- and allo-immune responses, whereas immune responses against infections and cancer are maintained.